<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Safe(r) ways to play biotech</title>
	<atom:link href="http://thecuriousinvestor.com/2009/08/18/safer-ways-to-play-biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://thecuriousinvestor.com/2009/08/18/safer-ways-to-play-biotech/</link>
	<description>A stock market and investing blog for the curious</description>
	<lastBuildDate>Tue, 08 Dec 2009 07:09:51 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
	<item>
		<title>By: Three Penny-Stock Winners in a Losing Market</title>
		<link>http://thecuriousinvestor.com/2009/08/18/safer-ways-to-play-biotech/comment-page-1/#comment-18008</link>
		<dc:creator>Three Penny-Stock Winners in a Losing Market</dc:creator>
		<pubDate>Tue, 18 Aug 2009 15:46:11 +0000</pubDate>
		<guid isPermaLink="false">http://thecuriousinvestor.com/?p=664#comment-18008</guid>
		<description>[...] Safe(r) ways to play biotech I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play . ISIS took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash po    Share and Enjoy: [...]</description>
		<content:encoded><![CDATA[<p>[...] Safe(r) ways to play biotech I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play . ISIS took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash po    Share and Enjoy: [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
